Consultations to begin as MoH prepares to roll out Pfizer vaccine for 5 to 11 age group

Home*Cover Story*News

Consultations to begin as MoH prepares to roll out Pfizer vaccine for 5 to 11 age group

Consultations are set to begin locally concerning the rollout of the Pfizer COVID vaccine for the 5 to 11 age group.
This follows the latest recommendation by the World Health Organisation, (WHO).

Minister of Health, Terrence Deyalsingh, announced during Saturday’s media briefing that the Pfizer vaccine was granted Emergency Use Authorization for children between ages 5 and 11 by the WHO, and as a result, the Ministry of Health has begun the process to rollout vaccines for this age group.

According to international reports, the suggestion comes after a meeting of the WHO Strategic Advisory Group of Experts to evaluate the shot.

However, Deyalsingh explained that there must first be a round of discussions for technical advice.

He said “The Chief Medical Officer will convene his Technical Advisory Group (TAG) on Monday to dissect and digest the updated Interim Guidelines which WHO put out yesterday. We will also be conferring with the Pan American Health Organization (PAHO) and Caribbean Public Health Agency (CARPHA) to look at their technical guidelines and technical details.”

“So far, this morning and last night when this Interim Guidelines came out, I personally have been in contact at a national level with Dr Faith B Yisrael (THA Health Secretary) to coordinate not only a national rollout but a national training and sensitisation programme for those who have to administer the vaccine. I have also alerted Nyan Gadsby-Dolly, Minister of Education, because this directly affects school children between the ages of 5 and 11,” Deyalsingh pointed out.

Deyalsingh said, “Once we have a position, we will come to the national population to discuss the national rollout. That is where we are. It is some good news, but we do have some Is to dot and some Ts to cross before we go full speed ahead to vaccinate this cohort.”

COMMENTS

WORDPRESS: 0
DISQUS: 0